Biomol Ther.
2021 May;29(3):268-272. 10.4062/biomolther.2021.032.
Antiviral Efficacy of Pralatrexate against SARS-CoV-2
- Affiliations
-
- 1Department of Microbiology, Institute for Viral Diseases, Korea University College of Medicine, Seoul 02841, Republic of Korea
- 2Biosafety Center, Korea University College of Medicine, Seoul 02841, Republic of Korea
- KMID: 2515274
- DOI: http://doi.org/10.4062/biomolther.2021.032
Abstract
- Novel coronavirus (SARS-CoV-2) has caused more than 100 million confirmed cases of human infectious disease (COVID-19) since December 2019 to paralyze our global community. However, only limited access has been allowed to COVID-19 vaccines and antiviral treatment options. Here, we report the efficacy of the anticancer drug pralatrexate against SARS-CoV-2. In Vero and human lung epithelial Calu-3 cells, pralatrexate reduced viral RNA copies of SARS-CoV-2 without detectable cytotoxicity, and viral replication was successfully inhibited in a dose-dependent manner. In a time-to-addition assay, pralatrexate treatment at almost half a day after infection also exhibited inhibitory effects on the replication of SARS-CoV-2 in Calu-3 cells. Taken together, these results suggest the potential of pralatrexate as a drug repurposing COVID-19 remedy.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Understandings and Prospects of Laboratory Diagnosis of SARS-CoV-2
- Challenges of Scaling Up SARS-CoV-2 Rapid Antigen Tests
- Changes in SARS-CoV-2 antibody titers 6 months after the booster dose of BNT162b2 COVID-19 vaccine among health care workers
- SARS-CoV-2 vaccine challenge based on spike glycoprotein against several new variants
- SARS-CoV-2-Specific T Cell Responses in Patients with COVID-19 and Unexposed Individuals
